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 Anxiety disorders are the most prevalent disorders in children and adolescents, 
affecting approximately 15-20% of individuals under the age of 18 (Salum et al, 2013). 
Clinical subgroups, like autism spectrum disorder (ASD) and fragile X syndrome (FXS), 
have an elevated risk of a co-occurring anxiety disorder. Despite the elevated risk of 
anxiety in these groups, few research studies have investigated the rates and predictors of 
anxiety disorders in adolescents with these ASD and FXS. In the current study, 
participants included males with FXS (n=31) or ASD (n=20) aged 16 to 24. Measures 
included the Children’s Interview for Psychiatric Symptoms-Parent Version (P-ChIPS), 
the Autism Diagnostic Observation Schedule-2 (ADOS-2), and the Leiter International 
Performance Scale-Revised (Leiter-R). Descriptive statistics indicated that 48% of the 
FXS adolescents met criteria for an anxiety disorder compared with 50% in ASD. 
Additionally, 13% of the FXS and 30% of the ASD sample met for multiple anxiety 
disorders. Across the FXS and ASD groups 35% versus 15% met for Specific Phobia, 
12% versus 30% met for Social Phobia and 33% versus 40% met for GAD, respectively. 
T-tests showed no significant differences within and across groups for those meeting 
criteria for an anxiety disorder verses those not meeting criteria for age, NVIQ growth 
scores, and ASD severity. Results of the binary logistic regression did not show age, 
NVIQ growth scores, or ASD severity as significant predictors of any anxiety disorder 
across FXS and ASD. Lastly, approximately 40% of participants with FXS who met 
criteria for an anxiety disorder were prescribed medications for anxiety, as compared iv  
iv	
to 20% of the participants with ASD who met criteria for an anxiety disorder. Logistic 
regression results showed that taking anxiety medications were not significantly 
predictive of meeting criteria for an anxiety diagnosis however anxiety medication use 
was predictive of group diagnosis. Our primary finding is that approximately half of the 
FXS and ASD sample met for an anxiety disorder based on DSM-V criteria. Further, This 
study is the first that directly compares rates of anxiety disorders across adolescents and 
adults with FXS and idiopathic ASD within a small range of ages, intellectual ability, and 
autism severity. Reduced rates of anxiety disorders may be indicative of adolescent or 
young adult males with lower intellectual functioning who have FXS or ASD.
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Anxiety disorders are among the most prevalent and debilitating disorders in 
children and adolescents, affecting approximately 15-20% of individuals under the age of 
18 (Beesdo, Knappe, & Pine, 2011; Salum, De Sousa, do Rosário, Pine, & Manfro, 
2013). Clinical subgroups are often at a higher risk for developing a comorbid anxiety 
disorder, which has been shown to reduce functioning across multiple domains (Simonoff 
et al. 2008; Kim et al, 2000). Autism spectrum disorder (ASD) and fragile X syndrome 
(FXS) are two clinical subgroups with an elevated risk of a co-occurring anxiety disorder. 
Nearly 60% of males with FXS meet criteria for ASD, and there is considerable overlap 
between ASD features and anxiety symptoms; thus, disentangling the presentation and 
prevalence of anxiety in FXS and those with ASD is critical for the accurate diagnosis of 
anxiety disorders and the subsequent development of targeted treatments. Despite the 
elevated risk of anxiety in both ASD and FXS, few research studies have investigated the 
prevalence of anxiety disorders in adolescents with these disorders and comorbid 
intellectual disability (ID).  
1.1 ANXIETY IN AUTISM SPECTRUM DISORDER 
Autism spectrum disorder (ASD) is a highly prevalent neurodevelopmental 
disorder that occurs in 1 in 68 children and is characterized by social-communication 
impairments and repetitive, restricted behaviors (American Psychiatric Association, 
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2013; Christensen et al., 2016). Anxiety is one of the most prevalent comorbid disorders 
in ASD youth (Magiati et al., 2015; van Steensel, Bögels, & Perrin, 2011; White, 
Mazefsky, & Dichter, 2014; White, Oswald, Ollendick, & Scahill, 2009). Population-
based studies utilizing gold standard diagnostic measures report that 40-50% of 
individuals with ASD meet diagnostic criteria for anxiety, but other studies report 
prevalence rates ranging from 11-84% (White, Oswald, Ollendick, & Scahill, 2009; van 
Steensel, Bögels, & Perrin, 2011; Simonoff et al., 2008). Previous studies also show a 
range of rates for specific anxiety disorders. For instance, reported rates in ASD range 
from 8–63% for Specific Phobia, 2-35% for Generalized Anxiety Disorder (GAD), and 6-
37% for Social Anxiety Disorder (Muris, Steerneman, Merckelbach, Holdrinet, & 
Meesters, 1998; Simonoff et al., 2008; Bellini, 2006; Green, Gilchrist, Burton, & Cox, 
2000; Leyfer et al., 2006; de Bruin, Ferdinand, Meester, de Nijs, & Verheij, 2007; Kerns 
et al., 2014). The wide variability in diagnostic rates highlights the challenges inherent in 
diagnosing anxiety disorders in ASD and reflects a heterogeneous research population 
with a range of ages and functioning levels, factors that likely impact anxiety presentation 
in ASD. Further, adults with ASD and comorbid ID were less likely to receive a 
community diagnosis of anxiety, despite parent-reported symptoms (Buck et al., 2014).  
Several factors contribute to the challenges of accurately diagnosing anxiety 
disorders in individuals with ASD. One barrier is the overlap in symptomatology between 
ASD and anxiety. For instance, social avoidance, obsessions and preoccupations, 
repetitive behaviors, fear of change, and atypical phobias are features of both ASD and 
anxiety (Kerns, Kendall, Wood, & Storch, 2017; Van Steensel, Bögels, & Wood, 2013). 
Additionally, evidence suggests that anxiety in ASD presents both prototypically and 
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atypically relative to the DSM-5 diagnostic characterization of anxiety (Kerns et al., 
2014). Thus, the present DSM-5 based measures of anxiety may not accurately reflect the 
atypical presentations of anxiety in ASD (Kerns et al., 2014). Furthermore, confounding 
individual differences such as ID, and difficulties with insight and self-report also 
contribute to the difficulty in accurately diagnosing anxiety disorders in individuals with 
ASD (Kerns et al., 2014; van Steensel et al., 2011). 
Examining potential risk factors for anxiety disorders can provide insight into the 
development of these disorders and can improve diagnostic accuracy in ASD. Although a 
number of studies have investigated risk factors for anxiety in ASD, the heterogeneity 
across studies has reported that age, intellectual ability, and ASD symptom severity have 
variable impacts on the presence of anxiety in ASD (Kerns et al., 2014; Sukhodolsky et 
al., 2008; Renno & Wood, 2014). Some studies suggest that individuals with ID are at 
higher risk of certain anxiety disorders (Sukhodolsky et al., 2008), while other studies 
have found similar rates of anxiety across both ID and normal IQ in ASD (van Steensel et 
al., 2011; Kuusikko et al, 2008). The impacts of ASD severity have also varied across 
studies with some studies finding no associations between ASD severity and anxiety 
(Sukhodolsky et al., 2008; Renno & Wood, 2014), while others report a relationship 
between greater ASD severity and fewer anxiety symptoms (Gadow, Sprafkin, & Nolan, 
2001; Wood & Gadow, 2010). Overall, these studies highlight that there are several 
individual factors that may increase the risk for anxiety in children and adolescents with 
ASD, but similar to the range of diagnostic rates, results vary across a diverse ASD 
population.  
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Most existing studies of anxiety in ASD have included heterogeneous samples in 
regards to ASD severity, age, and anxiety measurement, leading to the wide range of 
reported prevalence rates (11-84%). However, the majority of previous studies have not 
included individuals with ASD with an IQ below 70, because, in part, measuring anxiety 
accurately can be difficult in these individuals (van Steensel et al., 2011). An estimated 
56% of individuals with ASD have an IQ below 85, with 31.6% having an ID, thus we 
lack research on anxiety in around one-third of the ASD population ( Christensen et al., 
2016; Cordeiro, Ballinger, Hagerman, & Hessl, 2011). There is some evidence that 
individuals with an ID are four times more likely to present with anxiety symptoms than 
their neurotypical peers, yet anxiety disorders are not well understood in ASD subgroups 
of ID (Green, Berkovits, & Baker, 2014; Matson & Matson, 2015). Although 
characterizing anxiety in ASD is complex because of the heterogeneity within the 
disorder and the phenotypic overlap, this is an important effort given that co-occurring 
anxiety is clearly associated with poorer social functioning and increased difficulties in 
individual and family functioning in individuals with ASD (Kim, Szatmari, Bryson, 
Streiner, & Wilson, 2000; Simonoff et al., 2008; White et al., 2009). Thus, research on 
the prevalence and predictors of anxiety in more homogeneous and lower functioning 
ASD samples is essential for accurate identification and treatment of comorbid anxiety.  
1.2 ANXIETY IN FRAGILE X SYNDROME 
Fragile X syndrome (FXS) is a single-gene disorder caused by a CGG expansion 
mutation on the Fragile X Mental Retardation-1 (FMR1) gene. Expansion of more than 
200 CGG repeats in the FMR1 gene causes reduced production of the fragile X mental 
retardation protein (FMRP), a protein that is essential for typical brain development 
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(Hagerman, Lauterborn, Au, & Berry-Kravis, 2012; Schwarte, 2008). Reduced FMRP 
results in the FXS behavioral phenotype, which is characterized by shyness, avoidant eye 
contact, elevated states of physiological arousal, social-communication deficits, and ID 
(Bailey, Hatton, Mesibov, Ament, & Skinner, 2000; Hessl et al., 2001; Klusek, Roberts, 
& Losh, 2015; Rogers, Wehner, & Hagerman, 2001). Many of the core features of FXS 
are qualitatively similar to those of ASD, and approximately 60% of males with FXS also 
meet diagnostic criteria for ASD (Klusek et al., 2014; García-Nonell et al., 2008). 
Few studies have examined prevalence and severity of anxiety disorders in FXS. 
In fact, only one study to date has used a DSM-based diagnostic measure to assess rates 
of anxiety disorders in FXS (Cordeiro et al., 2011). The study included 58 males and 39 
females with FXS (5 – 27 years old) and used the Anxiety Disorders Interview Schedule 
(ADIS-IV) (Grisham, Brown, & Campbell, 2004), a clinical parent interview based on 
the DSM-IV. In this study, 86% of the sample met diagnostic criteria for any anxiety 
disorder, 65% met criteria for Specific Phobia, and 35% met criteria for Social Phobia. 
This study also examined the potential effects of age, ID, and ASD comorbidity on 
anxiety disorder diagnosis. Results indicated that older age, the presence of an ID, and 
the presence of ASD were associated with increased prevalence in certain anxiety 
disorders. Though the use of a DSM-based measure is a strength of this study, the 
heterogeneity of the sample (e.g., wide age range, inclusion of both males and females) 
makes it difficult to draw firm conclusions about the prevalence of anxiety disorders in 
FXS. Because FXS presents differently across sex, developmental level, and 
chronological age, more focused samples are needed in order to clarify the prevalence of 
anxiety disorders in certain subgroups of FXS.  
6	
1.3 THE PRESENT STUDY 
Overall, research on anxiety disorders in both ASD and FXS is limited and 
highlights the challenges associated with accurately measuring anxiety symptoms in 
neurodevelopmental disorders characterized by ID and social-communicative deficits. 
Though elevated rates of anxiety symptomatology have been reported in ASD and FXS, 
no studies to date have directly compared anxiety prevalence in these clinical subgroups 
from a cross-syndrome perspective using a DSM-based measure to determine anxiety 
diagnoses, so the application of diagnostic criteria across studies is unclear. Finally, it 
remains unclear how anxiety presents in individuals with ASD or FXS who have 
comorbid ID (IQ < 70). Individuals with a comorbid ID are at elevated risk for 
psychopathology like anxiety, but are understudied, as there are additional challenges to 
accurately measuring anxiety in lower functioning populations (van Steensel et al., 2011; 
White et al., 2009). Because comorbid anxiety is associated with increased risk for 
problems such as inattention, hyperactivity, impulsivity, and self-injurious and aggressive 
behaviors (Talisa, Boyle, Crafa, & Kaufmann, 2014), it is essential that we understand 
how to diagnose these disorders in high-risk populations like ASD and FXS. 
This study examined the prevalence and predictors of anxiety disorders to 
determine the diagnostic rates of anxiety disorders in adolescents with non-syndromic 
ASD compared to adolescents with FXS.  It was hypothesized that the genetic 
mechanisms of FXS confer elevated risk for anxiety resulting in higher rates of anxiety 
disorders in the FXS group compared to the ASD group. The second objective was to 
investigate ASD severity, nonverbal IQ (NVIQ), and age as predictors of anxiety 
disorders within ASD and FXS. Based on previous studies, it was hypothesized that older 
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age, lower NVIQ, and elevated ASD severity will contribute to increased anxiety risk, 
and that these factors would predict a diagnosis of anxiety in ASD and FXS. The third 
objective was to evaluate the rate of prescribed anxiety medications in these groups and 
to determine the relationship between anxiety medication use and anxiety disorders. It 
was expected that anxiety medication rates would be higher in the FXS group than the 
ASD group because FXS is often viewed as a medical diagnosis versus ASD which is 
viewed as a behavioral diagnosis (Hernandez et al., 2009). Further, it is hypothesized that 
individuals prescribed anxiety medications will be more likely to meet criteria for an 





Participants included males with non-syndromic ASD (n = 20) or FXS (n = 31) 
ranging from 16 to 24 years of age (M = 18.8, SD = 2.1). Females were excluded from 
the study because of the cognitive and clinical heterogeneity across sexes for both ASD 
and FXS (Rinehart, Cornish, & Tonge, 2011). Diagnosis of FXS was confirmed through 
genetic testing (> 200 CGG repeats on the FMR1 gene). In participants with non-
syndromic ASD previous diagnosis was confirmed for the present study using gold 
standard diagnostic measures. Additionally, all participants were required to be able to 
communicate verbally (minimum combination of at least three words) and speak English 
as their primary language. Participants were recruited through two complementary 
studies. The entire FXS sample (n = 31) and a portion of the ASD sample (n = 8) were 
recruited as a part of a longitudinal, multi-site study focused on the development of 
language during adolescence in ID (i.e., Matherly et al., in press). The remaining 12 
participants with non-syndromic ASD were recruited through a study of social-
communication profiles within families of children with FXS and non-syndromic ASD 
(i.e., Klusek et al., 2017). Despite recruitment efforts to match the FXS and ASD groups 




2.2 PROCEDURES   
Participants were assessed at the Neurodevelopmental Disorders Lab at the 
University of South Carolina over two days. Trained research staff members administered 
all behavioral assessments and parent interviews. Participant families were compensated 
for travel expenses and provided $50 for study participation. The Institutional Review 
Board at the University of South Carolina approved all study protocols. Assent was 
obtained from the participants and informed consent was obtained from the participant’s 
parent prior to beginning the assessment.  
2.3 MEASURES 
Anxiety Diagnosis. The Children’s Interview for Psychiatric Symptoms-Parent 
Version (P-ChIPS) is a DSM-IV based, structured psychiatric interview designed to 
assess the presence of psychiatric disorders in children and adolescents (Weller, Weller, 
Fristad, Rooney, & Schecter, 2000). The P-ChIPS was conducted with the parents of 
participants to measure the presence of anxiety disorders, including Specific Phobia, 
Social Anxiety Disorder, and Generalized Anxiety Disorder (GAD). The P-ChIPS 
follows the DSM-IV structure of symptom count, duration, and impairment but was 
adapted to reflect the DSM-5 criteria for the current study. The GAD DSM-5 criteria 
specify that symptoms of excessive worrying need to occur the majority of days and on 
multiple topics, and thus, frequency of worries had to be endorsed as often as “every day 
or every other day” to meet criteria for the DSM-5. Further, if only one fear or worry is 
present then GAD criteria are not met and the specific fear or worry is instead addressed 
in Specific Phobia. The DSM-5 P-ChIPS adaptations also included the deletion of the 
criteria that individuals over the age of 18 need to recognize their fear or anxiety as 
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irrational or excessive for Specific Phobia and Social Phobia. Further, Specific or Social 
Phobia symptoms must be present for at least a 6-month duration for the DSM-5.   
Published kappa coefficients on the PChIPS ranged from good to excellent for 
each anxiety disorder (GAD .86, Specific Phobia .76, and Social Phobia .72). Previous 
studies found the intra-class correlations for all three subtype groups in the excellent 
range (0.91-0.99), as well as overall agreement for each of the subtypes (GAD: 95.4%, 
Specific Phobia: 90.7%, Social Phobia: 90.7%) (Witwer & Lecavalier, 2010; Witwer, 
Lecavalier, & Norris, 2012). For the present study, a licensed clinical psychologist 
assessed reliability on 20% of the ASD and FXS sample. Overall agreement across all 
anxiety disorders was 100% for the ASD group and 92% for the FXS group.  
Autism Spectrum Disorder (ASD) Symptom Severity. The Autism Diagnostic 
Observation Schedule-Second Edition (ADOS-2) is a semi-structured, standardized 
assessment of communication, social interaction, play, and restricted and repetitive 
behaviors (Lord, Rutter, DiLavore, Risi, & Gotham, 2012). The ADOS-2 was 
administered and scored live by graduate-level professionals who had completed research 
reliability training. The ADOS-2 calibrated severity scores were used to reflect the 
overall severity of ASD symptoms as well as severity of symptoms in the social-
communication domains and restricted/repetitive behavior domains. Table 1 presents 
descriptive statistics for overall severity scores for overall behaviors across both ASD and 
FXS groups.  
Nonverbal Intellectual Ability (NVIQ). The Leiter-R is a test of nonverbal 
intelligence and cognitive abilities (Roid & Miller, 1997). The brief measure contains 
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four subtests consisting of Figure Ground, Form Completion, Sequential Order, and 
Repeated Patterns. Due to low cognitive abilities in these populations floor effects can 
significantly truncate standard scores, thus impacting analyses. Therefore, growth scale 
value scores, which are a true interval scale unlike standard scores, were used in analysis 
to limit floor effects. 
2.4 STATISTICAL ANALYSIS 
Analyses were conducted using RStudio Version 1.0.136 (2015). Data were 
analyzed for violations of assumptions including homogeneity of variance, normality of 
residuals, and multicollinearity. The analytic strategy was completed in multiple steps. 
First, descriptive statistics were run to calculate the rates of overall and specific anxiety 
disorder diagnoses (i.e., GAD, Specific, Social) in the ASD and FXS groups. Next, bi-
serial correlations were performed to assess associations between anxiety and age, NVIQ 
growth scores, and ASD severity. A logistic regression model was then conducted to 
analyze age, ASD severity, and NVIQ growth scores as predictors of anxiety disorders in 
ASD and FXS. Exploratory descriptive analyses were also conducted to investigate the 
rates of prescribed anxiety medications across the ASD and FXS groups. Finally, a 
logistic regression model was run to assess if anxiety medication was a predictor of 











Table 2.1 Participant Demographics for Each Diagnostic Group 
 
 FXS 
n = 31 
 ASD 
n = 20 
 
 




490.11(19.94) t(29.3) = 5.76,  







t(35.6) = 1.78,  





18.18(4.77) t(22.1) = -0.45,  
p = 0.656 
 






3.1 PREVALENCE OF ANXIETY DISORDERS IN ASD AND FXS  
Descriptive statistics were used to compute the rates of anxiety disorders in FXS 
and ASD. Findings indicate that 48% of the FXS adolescents met criteria for an anxiety 
disorder, with 13% meeting for multiple anxiety disorders. Similarly, 50% of adolescents 
with ASD met criteria for an anxiety disorder, and 30% met criteria for multiple anxiety 
disorders. Rates of specific anxiety diagnoses for each group can be found in Table 2. 
Further analysis showed no within- or between-group differences in age, NVIQ growth 
scores, or ASD severity for those meeting criteria for an anxiety disorder versus those not 
meeting criteria. (Tables 3.1 and 3.2).  
3.2 PREDICTORS OF ANXIETY IN ASD AND FXS 
Biserial correlations were run to examine the relationship between anxiety and 
age, NVIQ growth scores, and ASD severity within FXS and ASD groups. 
Multicollinearity was not violated for any predictors (r > .70, p > 0.05), although NVIQ 
growth scores were moderately correlated with clinical diagnosis (FXS or ASD) (r = 
.664). A logistic regression model was then used to determine if age, NVIQ growth 
scores, and ASD severity predicted anxiety by group. Results of the binary logistic 
regression did not show that age, NVIQ growth scores, or ASD severity were significant 
predictors of any anxiety disorder across FXS and ASD (Table 5). Given the limited 
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sample size, further inferential statistical tests were not conducted to examine predictors 
for anxiety disorder subtypes across FXS and ASD. 
3.3 MEDICATION USE IN ASD AND FXS 
Descriptive statistics were run to assess the rate of prescription anxiety 
medication use for both the FXS and ASD group. The analysis showed that 
approximately 40% of participants with FXS and ASD who met criteria for an anxiety 
disorder were currently taking prescribed medications for anxiety. Biserial correlations 
did not show a relationship between anxiety medications and an anxiety diagnosis (r = 
0.137) but did show a relationship between anxiety medications and group, FXS or ASD 
(r = 0.394). Logistic regression was then used to assess the relation between anxiety 
medication and anxiety diagnosis by group. Results showed that taking anxiety 
medications was not significantly predictive of meeting criteria for an anxiety diagnosis 
(b = -0.047, F(1, 50) = -0.074, p = .941), however anxiety medication use was more 
likely in FXS (b = 2.133, F(1, 50) = 2.577, p = .0099 . Further, across groups, only 36% 
of those meeting criteria for current anxiety were prescribed an anxiety medication and 
46% of the sample were prescribed an anxiety medication but did not meet criteria for 









Table 3.1 Number of Anxiety Disorders By Clinical Group 
 
Overall Anxiety     
FXS 
n = 31 
 ASD 
n = 20 
No Anxiety Disorder  51.6% (n = 16)  50% (n = 10) 
One Anxiety Disorder 48.4% (n = 11)  50% (n = 7) 
Multiple Anxiety Disorders 12.9% (n = 4)  30% (n = 3) 
 
Table 3.2 Rates of Specific Anxiety Disorders By Clinical Group 
 
Anxiety Subtype  
FXS 
n = 31 
 ASD 
n = 20 
GAD 32.3% (n = 10)  40% (n = 8) 
Specific Phobia 35.5% (n = 11)  15% (n = 3) 














Table 3.3 Descriptive Statistics Between Anxiety and Non-Anxiety Within FXS and ASD 
 FXS+Anxiety 
n = 16 
FXS 
n = 16 
  
 M      SD M      SD t-test  
NVIQ Growth Scores 460.67(11.22) 459.31(16.88) -0.29 




6.48(3.69) 5.62(2.45) -0.77 




18.71(2.21) 18.70(1.92) -0.02 
p = 0.98 
 
 
  ASD+Anxiety 
n = 10 
ASD 
n = 10 
 
  M      SD M      SD t-test 
NVIQ Growth Scores  495.90(15.55) 483.70(21.79) -1.44 
p = 0.17 
ASD Severity 
 
 7.50(1.65) 6.90(2.18) -0.69 
p = 0.50 
Age 
 
 18.28(1.95) 19.60(2.33) 1.38 
p = 0.19 
 





Table 3.4 Descriptive Statistics Between Anxiety and Non-Anxiety Across FXS and ASD 
 Anxiety 
n = 25 
Non-Anxiety 
n = 26  
  






p = 0.32 
 
ASD Severity 6.26(2.18) 5.70(2.20) -0.87 
p = 0.39 
 
Age 17.99(4.15) 19.02(2.13) 1.11 
p = 0.27 
 
 
Note. M = Mean. SD = Standard Deviation. No significant differences were detected at 
p<.05. 
 
Table 3.5 Logistic Regression for NVIQ Growth Scores, ASD Severity, and Age 
Predicting Anxiety By ASD/FXS Group 





p = 0.08 
ASD Severity 0.13(0.15) 
p = 0.37 
Age -0.01(0.01) 
p = 0.43 
Group 0.92(0.91) 





Anxiety is highly prevalent in both ASD and FXS with estimated rates 
significantly elevated above neurotypical populations. This is the first study to contrast 
rates of anxiety using a DSM-V based measure across adolescent males with ASD or 
FXS, most of whom have ID. We found that approximately half of the sample for both 
ASD and FXS met DSM-V criteria for an anxiety disorder. The study did not find 
significant differences across age, NVIQ, or ASD severity for those meeting criteria for 
an anxiety disorder versus those who did not meet criteria for an anxiety disorder within 
the sample. Additionally, results did not show age, NVIQ, or ASD severity as significant 
predictors of an anxiety disorder across FXS or ASD. Thus, in a somewhat homogeneous 
sample, age, NVIQ, and ASD severity are not associated with anxiety in low functioning 
clinical subgroups.  
4.1 RATES OF ANXIETY DISORDERS IN ASD AND FXS  
 Half of the ASD sample met criteria for at least one anxiety disorder, 
which is generally consistent with previous population based studies (White et al., 2014). 
The ASD group showed the highest rate of GAD at 40% of the sample, which is higher 
than the previously reported range of 2-35% (Bellini, 2006; Green, Gilchrist, Burton, & 
Cox, 2000; Leyfer et al., 2006) and might indicate that in general, adolescents with lower 
functioning ASD maybe at a higher risk for GAD. Another potential hypothesis is that 
features of ASD, such as atypical fears and sensory aversions, are captured under GAD 
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(Kerns et al., 2017; Kerns et al., 2014). Social Anxiety Disorder (30%) and Specific 
Phobia (15%) both fell within the previously reported ranges of 6-37% and 8–63%, 
respectively (Muris et al., 1998; Simonoff et al., 2008; de Bruin, Ferdinand, Meester, de 
Nijs, & Verheij, 2007; Kerns et al., 2014; Leyfer et al., 2006), suggesting that these 
specific anxiety disorders are elevated in ASD regardless of intellectual level.  
Overall, both similarities and differences were noted between the current study 
and the Cordeiro et al. (2011) study of anxiety in FXS. Specific Phobia was the highest 
reported anxiety disorder in both the current study (40%) and in the Cordeiro et al. (2011) 
anxiety study (59.6%). Differences were seen in both rates of GAD, 24% compared to 
33% in the current study, and Social Phobia, 37% compared to 13% in the current study. 
It is possible that the differences in the rates of GAD and Social Phobia are related to the 
heterogeneity between the two samples. The previous study included a wider range of 
ages and both sexes, whereas our study was more homogeneous in both age and sex. 
Overall the anxiety disorders in this study and in previous literature are elevated above 
male neurotypical adolescents’ lifetime prevalence of anxiety disorders; approximately 
30% for an anxiety disorder, 1.5% for GAD, 7% for Social Phobia, and 17% for Specific 
Phobia (Merikangas, et al, 2010). While the specific anxiety disorder rates differed 
between the ASD and FXS groups, approximately half of each group met DSM-5 criteria 
for an anxiety disorder. The high rate of anxiety disorders in both samples might be 
indicative of additional phenotypic overlap.  
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4.2 RELATIONSHIP BETWEEN PREDICTORS AND ANXIETY DISORDERS 
IN ASD AND FXS 
Previous research has shown that cognitive ability, ASD severity, and age can 
predict anxiety disorders in ASD and FXS, yet the current study did not find a significant 
relationship between these factors and meeting criteria for an anxiety disorder. One 
explanation is that the current study sample was focused on a low-functioning sample 
within a small age range, and further, significant differences were not seen across the 
anxious and non-anxious groups for age, NVIQ, or ASD severity. Correlations also 
showed a moderate relationship between FXS or ASD diagnosis and NVIQ, and the 
regression model showed NVIQ trending towards significance in predicting anxiety. This 
trend suggests that even in an overall low-functioning sample, NVIQ plays a significant 
role in our ability to measure and detect anxiety. This finding is particularly important in 
developing measures and understanding how to best capture features of anxiety in low-
functioning or nonverbal samples. Overall, a larger sample would allow for further 
analysis into potential predictors of specific anxiety disorders, as the prevalence of each 
specific anxiety disorder varied between the ASD and FXS groups. 
This study also contributes to refining the ASD and FXS anxiety phenotypes. 
Anxiety is clearly an important dimension to consider in understanding outcomes in these 
clinical groups since approximately half of each group met DSM-5 criteria for an anxiety 
disorder. Further, behavioral treatment studies for anxiety in individuals with low 
functioning ASD or FXS have not been conducted. Although evidence-based treatments 
for anxiety are effective in high functioning individuals with ASD, the majority of these 
interventions have not been studied and are not appropriate for low-functioning 
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individuals with neurodevelopmental disorders (Sukhodolsky et al., 2013). Thus, further 
research is necessary to understand effective treatments for anxiety in these lower 
functioning clinical populations. 
4.3 MEDICATION USE IN RELATION TO ANXIETY DISORDERS IN ASD 
AND FXS 
Medication is a primary form of treatment for anxiety with 40% of the FXS and 
ASD participants who met criteria for a current anxiety disorder receiving medication for 
anxiety in this study. These rates are similar to previous research in FXS that indicated 
that approximately 50% of males with FXS are prescribed medication for anxiety (Berry-
Kravis & Potanos, 2004; Berry-Kravis, Knox, & Hervey, 2011). Studies have shown 
anxiety medications like SSRIs are effective in treating anxiety in around 50% of 
individuals with FXS yet there are no behavioral interventions developed for anxiety in 
FXS (Erickson et al., 2017; Hagerman et al., 2012). In ASD, however, previous studies 
show that approximately 30% of individuals are prescribed psychotropic medications but 
that rate climbs to 77-80% when diagnosed with comorbid anxiety (Coury et al., 2012; 
Rosenberg et al., 2010). This might suggest that individuals with ASD and ID are less 
likely to receive an anxiety diagnosis, and therefore, less likely to receive a 
pharmacological intervention for treatment. 
In the present study, of those taking an anxiety medication, approximately 53% 
met for an anxiety disorder. Additionally, 64% of individuals meeting for an anxiety 
disorder were not medicated for anxiety. One possible explanation is that the P-ChIPS 
measures current anxiety (occurring for at least 6 months) and not past anxiety. Thus, the 
potential mismatch of prescribed anxiety medications and the anxiety diagnosis on the P-
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ChIPS might indicate that the medications are effective in suppressing current anxiety 
symptomology, and thus, causing them not to meet criteria for present anxiety. However 
close to two-thirds of the sample that met criteria for an anxiety disorder were not 
receiving any anxiety specific pharmacological treatment at the time of the study, which 
indicates a potential gap between diagnosis and treatment in low functioning individuals 
with anxiety. One reason for this gap maybe the perceived efficacy of anxiety 
medications by parents of children or adolescents with FXS, with one study finding that 
the majority of parents found anxiety medications “somewhat” effective to “not at all” 
effective (Bailey et al., 2012). Additionally, anxiety is often considered a part of the 
phenotype of FXS, and therefore, additional treatment may not be sought. 
4.4 LIMITATIONS AND FUTURE DIRECTIONS 
Despite being the first study to examine DSM-5 anxiety diagnoses in adolescent 
males with non-syndromic ASD and FXS, our study had several limitations. First, our 
analysis was restricted by the small sample size of the population of males with low 
functioning ASD and males with FXS. Further, the mean NVIQ of the ASD group was 
below 70, yet there was still a significant difference between the groups NVIQ. An 
additional limitation to measuring anxiety in a low functioning population is that the 
diagnoses were made on parent report and not self-reported by participants. Thus, there 
were likely instances where parents were unsure if their son was experiencing anxiety 
symptoms that were not verbalized or observed. Our future research will include multi-
dimensional measures of anxiety such as physiological (heart rate, cortisol) and 
experimental observation (LAB-TAB, Anx-DOS) and use of measures developed 
specifically for individuals with neurodevelopmental disorders (ADIS/ASDD). 
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4.5 CONCLUSIONS 
 This study supports the growing literature that anxiety is highly prevalent 
and pervasive in both ASD and FXS. The majority of the literature in ASD, however, has 
spanned a wide range of ages and functioning levels, and does not typically include 
individuals with ASD and ID. The research on anxiety in FXS is more limited and 
primarily consists of broadband screening measures of anxiety across a wide age range. 
Prior to this study, research had yet to compare anxiety presentation and moderating 
factors in adolescents of these two neurodevelopmental disorder subgroups. Research 
into anxiety disorders and predictors within these two groups is important because there 
are clear negative impacts of anxiety, like increased aggression and self-injurious 
behaviors and lower adaptive skills, when comorbid with neurodevelopmental disorders 
such as ASD and FXS (Talisa et al., 2014; White et al., 2009). This study delves deeper 
into the DSM-5 anxiety presentations in a homogeneous sample of male adolescents with 
low functioning ASD and adolescent males with FXS. As a result, there are clear clinical 
implications for diagnosing anxiety comorbid to neurodevelopmental disorders and ID 
and treatment implications for the development of appropriate cognitive, behavioral 
treatments and pharmacological treatments. 
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